3 Unpopular Stocks We Keep Off Our Radar

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.

PepsiCo (PEP)

Consensus Price Target: $172 (9% implied return)

With a history that goes back more than a century, PepsiCo (NASDAQ:PEP) is a household name in food and beverages today and best known for its flagship soda.

Why Are We Wary of PEP?

Falling unit sales over the past two years imply it may need to invest in product improvements to get back on track Anticipated sales growth of 4.3% for the next year implies demand will be shaky Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 1.2 percentage points

PepsiCo is trading at $157.80 per share, or 18x forward P/E. Check out our free in-depth research report to learn more about why PEP doesn’t pass our bar.

Dover (DOV)

Consensus Price Target: $248.63 (9.4% implied return)

A company that manufactured critical equipment for the United States military during World War II, Dover (NYSE:DOV) manufactures engineered components and specialized equipment for numerous industries.

Why Does DOV Give Us Pause?

Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 5.8% annually Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability

Dover’s stock price of $227.26 implies a valuation ratio of 3.5x forward price-to-sales. Read our free research report to see why you should think twice about including DOV in your portfolio, it’s free.

Teleflex (TFX)

Consensus Price Target: $132.78 (9% implied return)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Why Do We Steer Clear of TFX?

Annual sales declines of 18.3% for the past two years show its products and services struggled to connect with the market during this cycle Constant currency revenue growth has disappointed over the past two years and shows demand was soft Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 20.6 percentage points

Story Continues

At $121.82 per share, Teleflex trades at 18.1x forward P/E. Check out our free in-depth research report to learn more about why TFX doesn’t pass our bar.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

View Comments